Funding
← Back to your selection

Fidelity Management & Research Company

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026

Fidelity Management & Research Company is an investment adviser within Fidelity Investments, managing portfolios for investment funds and other clients, including exposure to private companies.

Fidelity’s research-led technology investing examines both public and private businesses. Its AI framework covers the computing components and infrastructure needed to run models as well as companies applying the technology, connecting private-company analysis with the wider listed market.

FMR manages capital through investment products and client mandates. A financing attributed to the manager can therefore involve fund-managed capital, rather than a standalone accelerator or a standard programme with a fixed investment offer for founders.

Sources
Rounds participated in
7
Confirmed lead rounds
0
6 roles undisclosed
New companies
7
First participation on record · 0 follow-on
Funding in participating rounds
$1.4B
7 disclosed · full round size, not this investor’s share

By stage

Series C+4
Series B3

By primary sector

Biotech7

By country

United States5
Australia1
United Kingdom1

Rounds

7 in this selection
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
AdvanCell

AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.

$315MSeries D
Role not disclosed
City Therapeutics

City Therapeutics develops RNA-interference therapeutics and an engineering platform across disease areas.

$99.5MSeries B
Role not disclosed
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries D
Role not disclosed
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed